Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,401 to 2,420 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Basic Implementation Approach vs Enhanced Implementation Approach: Presence of an Order for Benzodiazepine Medication | 1,025 of 1,519 1,117 of 1,687 | 1.3 points -2.0 to 4.5 | 3,206 | NCT02383173 Evaluation of Methods for Implementation of a Comfort Care Order Set |
| Basic Implementation Approach vs Enhanced Implementation Approach: Presence of Restraints | 86 of 1,519 73 of 1,687 | 1.3 points -0.2 to 2.9 | 3,206 | NCT02383173 Evaluation of Methods for Implementation of a Comfort Care Order Set |
| Basic Implementation Approach vs Enhanced Implementation Approach: Presence of an Active Opioid Order at Time of Death | 1,330 of 1,519 1,543 of 1,687 | -3.9 points -6.1 to -1.8 | 3,206 | NCT02383173 Evaluation of Methods for Implementation of a Comfort Care Order Set |
| Fasiglifam 50 mg vs Placebo: serious adverse events | 201 of 1,601 197 of 1,603 | 0.3 points -2.0 to 2.6 | 3,204 | NCT01609582 Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease |
| CYD Dengue Vaccine Group vs Control Group: deaths from any cause | 3 of 2,131 2 of 1,072 | -0.0 points -0.5 to 0.3 | 3,203 | NCT01983553 Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study |
| CYD Dengue Vaccine Group vs Control Group: serious adverse events | 3 of 2,131 2 of 1,072 | -0.0 points -0.5 to 0.3 | 3,203 | NCT01983553 Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study |
| R10933 + R10987 vs Placebo: Immunogenicity as Measured by Anti-drug Antibodies (ADAs) to REGN10933 | 1,319 of 1,595 1,544 of 1,606 | -13.4 points -15.6 to -11.4 | 3,201 | NCT04452318 COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay |
| R10987 + R10987 vs Placebo: Immunogenicity as Measured by Neutralizing Anti-drug Antibody (NAb) to REGN10987 | 160 of 1,595 27 of 1,606 | 8.4 points 6.8 to 10.0 | 3,201 | NCT04452318 COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay |
| R10987 +R10933 vs Placebo: Immunogenicity as Measured by Anti-drug Antibodies (ADAs) to REGN10987 | 1,251 of 1,595 1,500 of 1,606 | -15.0 points -17.3 to -12.6 | 3,201 | NCT04452318 COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay |
| R10933 + R10987 vs Placebo: Immunogenicity as Measured by Neutralizing Anti-drug Antibody (NAb) to REGN10933 | 33 of 1,595 4 of 1,606 | 1.8 points 1.1 to 2.7 | 3,201 | NCT04452318 COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay |
| Conventional Dispatcher CPR vs NAD-CPR: Number of Participants With Pre-Hospital Return of Spontaneous Circulation (ROSC) | 107 of 1,498 223 of 1,696 | -6.0 points -8.1 to -3.9 | 3,194 | NCT02010151 Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation |
| Conventional Dispatcher CPR vs NAD-CPR: deaths from any cause | 1,363 of 1,498 1,480 of 1,696 | 3.7 points 1.6 to 5.9 | 3,194 | NCT02010151 Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation |
| Conventional Dispatcher CPR vs NAD-CPR: Number of Participants With Good Neurological Recovery | 68 of 1,498 140 of 1,696 | -3.7 points -5.4 to -2.0 | 3,194 | NCT02010151 Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation |
| Conventional Dispatcher CPR vs NAD-CPR: Number of Participants Surviving at Hospital Discharge | 135 of 1,498 216 of 1,696 | -3.7 points -5.9 to -1.6 | 3,194 | NCT02010151 Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation |
| Conventional Dispatcher CPR vs NAD-CPR: serious adverse events | 1,363 of 1,498 1,480 of 1,696 | 3.7 points 1.6 to 5.9 | 3,194 | NCT02010151 Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation |
| aH5N1c vs Placebo: deaths from any cause | 11 of 2,395 1 of 796 | 0.3 points -0.3 to 0.7 | 3,191 | NCT02839330 A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age |
| aH5N1c vs Placebo: serious adverse events | 161 of 2,395 74 of 796 | -2.6 points -5.0 to -0.5 | 3,191 | NCT02839330 A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age |
| Intervention vs Control: Severe Maternal Outcome | 25 of 1,552 25 of 1,639 | 0.1 points -0.8 to 1.0 | 3,191 | NCT04060667 Wireless Physiologic Monitoring in Postpartum Women |
| Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With a First Occurrence of Symptomatic COVID-19 | 0 of 2,142 6 of 1,044 | -0.6 points -1.2 to -0.2 | 3,186 | NCT04649151 A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 |
| Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With Asymptomatic SARS-CoV-2 Infection | 20 of 2,142 16 of 1,044 | -0.6 points -1.6 to 0.2 | 3,186 | NCT04649151 A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 |
Code
curl "https://conductscience.org/api/comparisons/v1?page=121"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=121
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02383173-3ad863be",
"title": "Basic Implementation Approach vs Enhanced Implementation Approach: Presence of an Order for Benzodiazepine Medication",
"summary": "1025 of 1519 against 1117 of 1687; risk difference 1.3 points, 95% interval -2.0 to 4.5; NCT02383173, Evaluation of Methods for Implementation of a Comfort Care Order Set",
"record": "/library/comparisons/NCT02383173-3ad863be",
"nct_id": "NCT02383173",
"kind": "outcome",
"participants": 3206,
"risk_difference": {
"value": 0.012663933194747568,
"lower": -0.019995564954954782,
"upper": 0.04519638484719493
},
"group_1": "1,025 of 1,519",
"group_2": "1,117 of 1,687",
"difference": "1.3 points",
"interval": "-2.0 to 4.5",
"trial_title": "Evaluation of Methods for Implementation of a Comfort Care Order Set"
},
{
"id": "NCT02383173-67460b5e",
"title": "Basic Implementation Approach vs Enhanced Implementation Approach: Presence of Restraints",
"summary": "86 of 1519 against 73 of 1687; risk difference 1.3 points, 95% interval -0.2 to 2.9; NCT02383173, Evaluation of Methods for Implementation of a Comfort Care Order Set",
"record": "/library/comparisons/NCT02383173-67460b5e",
"nct_id": "NCT02383173",
"kind": "outcome",
"participants": 3206,
"risk_difference": {
"value": 0.013344114248563833,
"lower": -0.001742320251744367,
"upper": 0.028813031239893386
},
"group_1": "86 of 1,519",
"group_2": "73 of 1,687",
"difference": "1.3 points",
"interval": "-0.2 to 2.9",
"trial_title": "Evaluation of Methods for Implementation of a Comfort Care Order Set"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=122",
"request_id": "1Dgd0o7oNY5QgGsb"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant